<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108560</url>
  </required_header>
  <id_info>
    <org_study_id>ZSTS201701</org_study_id>
    <nct_id>NCT03108560</nct_id>
  </id_info>
  <brief_title>Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer</brief_title>
  <official_title>A Multi-center, Randomized-controlled, Open-label Clinical Trial: Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical Univeristy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo No.2 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence rate of ground-glass opacity (GGO) has been increasing these years. A great
      number of retrospective studies suggested that sublobar resection was better for some GGO
      patients. However, no prospective clinical study supports the perspective. This study is
      prospective, multi-center, randomized-controlled. The aim of this study is to investigate
      whether sublobar resection is inferior to lobectomy for cT1N0M0 non-small-cell lung cancer or
      not.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>five years after surgery</time_frame>
    <description>survival status of patients after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>five years after surgery</time_frame>
    <description>recurrence status of patients after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local and distant recurrence rates</measure>
    <time_frame>five years after surgery</time_frame>
    <description>recurrence rate of local and distant locations respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: forced expiratory volume in 1 second (FEV1) in liter</measure>
    <time_frame>3rd, 6th, 12th, and 24th month after surgery</time_frame>
    <description>FEV1 of patients after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: forced vital capacity (FVC) in liter</measure>
    <time_frame>3rd, 6th, 12th, and 24th month after surgery</time_frame>
    <description>FVC of patients after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function: diffusing capacity of the lungs for carbon monoxide (DLCO) in mL/min/mmHg</measure>
    <time_frame>3rd, 6th, 12th, and 24th month after surgery</time_frame>
    <description>DLCO of patients after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity rate</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>the rates of complications related to treatment during perioperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>the rates of death related to treatment during perioperative period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Sublobar group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sublobar resection, including wedge resection and segmentectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lobectomy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive lobectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sublobar resection</intervention_name>
    <description>Patients receive sublobar resection, which includes wedge resection and segmentectomy.</description>
    <arm_group_label>Sublobar group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lobectomy</intervention_name>
    <description>patients receive lobectomy</description>
    <arm_group_label>Lobectomy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cT1N0M0 non-small-cell lung cancer

          -  ground-glass opacity, ≤2cm, GGO≥25%

          -  eligible for both lobectomy and sublobar resection

          -  intraoperative pathology is minimally-invasive adenocarcinoma or invasive
             adenocarcinoma

          -  intraoperative pathology of biopsied station 10 lymph node is negative

        Exclusion Criteria:

          -  intraoperative pathology is benign nodule, atypical adenomatous hyperplasia, or
             adenocarcinoma in-situ

          -  intraoperative pathology of biopsied station 10 lymph node is positive

          -  multiple GGOs, lesions other than dominant lesion are malignant or &gt;5mm

          -  history of thoracic surgery

          -  history of malignancy in recent 5 years

          -  unstable systemic disease

          -  patients with psychiatric disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Di Ge, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junjie Xi, MD</last_name>
    <phone>8602164041990</phone>
    <phone_ext>2017</phone_ext>
    <email>xi.junjie@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Di Ge, MD</last_name>
      <phone>13681975917</phone>
      <email>ge.di@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sublobar resection</keyword>
  <keyword>lobectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data of all case report forms are to be collected and shared with other researchers at the end of followup.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

